Related Experiment Videos
[Evaluation of latamoxef in neonates]
The Japanese Journal of Antibiotics
|September 1, 1983
Summary
Latamoxef (LMOX) demonstrates excellent activity against Gram-negative bacteria, but less potency against Gram-positive strains. Pharmacokinetic studies in infants show LMOX has a longer serum half-life in newborns compared to older infants.
Area of Science:
- Pharmacology
- Microbiology
- Neonatal Medicine
Background:
- Assessing the efficacy and pharmacokinetics of latamoxef (LMOX) for treating infections in newborn infants.
- Evaluating LMOX's antibacterial spectrum against common Gram-negative and Gram-positive pathogens.
Observation:
- Latamoxef exhibited excellent minimum inhibitory concentrations (MICs) against various Gram-negative bacteria, including E. coli and H. influenzae.
- Antibacterial activity was less potent against Pseudomonas aeruginosa and Gram-positive bacteria like S. pyogenes and S. aureus.
- Intravenous administration in neonates resulted in mean serum concentrations of 38.5 µg/ml at 0.5 hours, decreasing to 15.5 µg/ml at 6 hours.
- Serum half-life was notably longer in newborns (4.46 hours) compared to older infants (1.96 hours).
Findings:
- LMOX demonstrates potent in vitro activity against key Gram-negative pathogens relevant to neonatal infections.
- Pharmacokinetic data indicate prolonged drug exposure in newborn infants, suggesting potential for effective treatment.
- Urinary recovery rates were 32.3% in newborns and 49.7% in suckling infants over 6-8 hours.
Implications:
- Latamoxef shows promise as a treatment option for Gram-negative bacterial infections in neonates.
- Understanding LMOX pharmacokinetics in different infant age groups is crucial for optimizing dosing regimens.
- Further clinical studies are warranted to confirm safety and efficacy in the neonatal population.